R Goldsmith1, A K Chan1, B A Paes2, M D Bhatt1. 1. Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada. 2. Division of Neonatology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada.
Abstract
OBJECTIVE: The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment. STUDY DESIGN: Retrospective study of neonates with thrombosis treated between January 2008 and December 2014. RESULT: Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg(-1), respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml(-1)) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state. CONCLUSION: Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.
OBJECTIVE: The objective of our study was to determine the feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates, and to assess response to treatment. STUDY DESIGN: Retrospective study of neonates with thrombosis treated between January 2008 and December 2014. RESULT: Nineteen premature and 21 term neonates were treated with whole milligram doses of enoxaparin. The mean starting and therapeutic enoxaparin doses were 1.72±0.17 and 1.86±0.17 mg kg(-1), respectively. Twenty-five (64%) reached therapeutic antifactor Xa (anti-Xa) levels with the starting dose, whereas 14 (36%) required dose adjustments. One neonate reached a supratherapeutic anti-Xa level (>1.0 IU ml(-1)) in the loading phase. No bleeding episodes occurred. The mean treatment duration was 12 weeks. Among 34 (85%) evaluable patients, 23 (68%) had a complete response, 9 (26%) partial and 2 (6%) had a stable thrombotic state. CONCLUSION: Whole milligram dosing of enoxaparin for thrombosis is feasible, safe and effective in premature and term neonates.
Authors: Maisoon Abdullah Ghaleb; Nick Barber; Bryony D Franklin; Vincent W S Yeung; Zahra F Khaki; Ian C K Wong Journal: Ann Pharmacother Date: 2006-09-19 Impact factor: 3.154
Authors: Janet I Malowany; David C Knoppert; Anthony K C Chan; Dion Pepelassis; David S C Lee Journal: Pharmacotherapy Date: 2007-09 Impact factor: 4.705
Authors: Mary E Bauman; Mark J Belletrutti; Laszlo Bajzar; Karina L Black; Stefan Kuhle; Michelle L Bauman; M Patricia Massicotte Journal: Thromb Haemost Date: 2009-01 Impact factor: 5.249